Life ScienceCompany
iBio M&A Summary
iBio has acquired 1 company, including 1 in the last 5 years. It has also divested 1 asset.
It’s largest disclosed sale occurred in 2024, when it sold iBio - Preclinical PD-1 Agonist Antibody Program to Otsuka Pharmaceutical for $53M. iBio has acquired in 1 US state. The Company’s most targeted sectors include life science (100%).
iBio Business Overview
Where is iBio headquartered?
iBio is headquartered in Bryan, Texas.
What is iBio’s revenue?
iBio disclosed revenue of 2M USD for 2021 and 2M USD for 2020.
How many employees does iBio have?
iBio has 26 employees.
What sector is iBio in?
iBio is a life science company.
M&A Summary
-
M&A Total Activity2
- M&A Buy Activity1
- M&A Sell Activity1
- Total Sectors Invested 1
- Total Countries Invested 1
- M&A Buy/Sell Connections 1